Are late preterm infants as susceptible to RSV infection as full term infants?

Area of Science:

• Neonatology
• Pediatric Infectious Diseases
• Respiratory Medicine

Background:

• Preterm infants, especially those born before 33 weeks gestational age (GA), are at high risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI).
• Recent evidence indicates that late preterm infants (34 to 36 weeks GA) are equally susceptible to severe RSV LRTI.
• These infants experience increased morbidity and mortality compared to full-term infants due to immature immune systems and underdeveloped lungs.

Purpose of the Study:

• To highlight the significant risk of severe RSV LRTI in late preterm infants.
• To underscore the importance of palivizumab prophylaxis for preventing RSV-related complications.
• To emphasize the need for identifying additional risk factors to optimize prophylaxis strategies.

Main Methods:

• Review of recent studies on RSV LRTI in preterm infants.
• Analysis of factors contributing to severe LRTI, including immune system immaturity and lung development.
• Evaluation of the effectiveness and necessity of palivizumab prophylaxis.

Main Results:

• Late preterm infants (34-36 weeks GA) are as susceptible to severe RSV LRTI as earlier preterm infants.
• Factors like immune system immaturity and interrupted lung development contribute to increased severity.
• Morbidity and mortality rates are significantly higher in late preterms versus term infants.

Conclusions:

• Severe RSV LRTI poses a substantial threat to late preterm infants.
• Palivizumab prophylaxis is crucial for mitigating RSV risk in this population.
• Further identification of risk factors is essential for tailoring palivizumab administration to high-risk individuals.